Dannye dolgosrochnogo nablyudeniya podtverzhdayut, chto razrabotannyy kompaniey Novartispreparat TasignaR prevoskhodit preparat GlivekR po snizheniyu riska progressirovaniyazabolevaniya u patsientov s vpervye diagnostirovannym khronicheskim mieloleykozom
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2011-03-01
|
| Series: | Современная онкология |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/29421 |